Who is sponsoring NCT03293589?

NCT03293589 is sponsored by University Hospital Erlangen.

What drugs are being tested in NCT03293589?

Interventions in NCT03293589: open revascularization, endovascular revascularization.

What condition does NCT03293589 study?

NCT03293589 studies End-stage Renal Disease, Critical Limb Ischemia.

Is NCT03293589 still recruiting?

NCT03293589 is currently completed. Last updated 26 March 2020.

Last reviewed 2020-03-26 · How we verify

NCT03293589: OERESRD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Versus Endovascular Revascularization in Patients With End-stage Renal Disease

Completed Last updated 26 March 2020

What this trial tests

trial testing open revascularization in End-stage Renal Disease in 77 participants. Completed in 30 October 2017.

Timeline

1 July 2017

Primary endpoint
20 September 2017

30 October 2017

Quick facts

Lead sponsor	University Hospital Erlangen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	77
Start date	1 July 2017
Primary completion	20 September 2017
Estimated completion	30 October 2017
Sites	1 location across Germany

Drugs / interventions tested

open revascularization
endovascular revascularization

Conditions studied

End-stage Renal Disease — all drugs for End-stage Renal Disease →
Critical Limb Ischemia — all drugs for Critical Limb Ischemia →

Sponsor

University Hospital Erlangen

Who can join

Eligibility, any sex, with End-stage Renal Disease or Critical Limb Ischemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of patients with end-stage renal disease and critical limb ischemia still poses challenges to vascular medicine due to limited survival, comorbidities and infrapopliteal involvement of arteriosclerosis in these patients. Most optimal vascular therapy mode has not been finally decided in these patients. Therefore retrospective analysis of patients receiving open surgical and endovascular revascularisation was performed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for End-stage Renal Disease

Currently open trials in the same condition.

NCT06755372 — The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Populati · recruiting
NCT05473299 — Xeltis Hemodialysis Access Graft: aXess Pivotal Study · NA · active not recruiting
NCT05154773 — Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication · NA · active not recruiting
NCT03994497 — Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Rena · NA · recruiting
NCT02728817 — Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation · NA · active not recruiting

Other University Hospital Erlangen trials

Trials by the same sponsor.

NCT07347535 — Non-invasive MSOT Examination of Muscle Oxygenation in Athletes and PAD Patients · not yet recruiting
NCT06994260 — Diagnostic Imaging of Vascular Malformations Using MSOT and ULM · not yet recruiting
NCT06966297 — MSOT_PI Analysis of Revascularization Procedure Using Optoacoustic Imaging · completed
NCT05773547 — Investigation of the Learning Effect in the Measurement of Circulation in Calf Muscle Using MSOT · unknown
NCT05110677 — Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03293589 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Erlangen
Last refreshed: 26 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03293589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing